Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Commission for the Evaluation of Diagnostic, Prognostic, and Predictive Technologies established at the HAS in France

In the middle of April 2023, the French National Authority for Health (HAS) published a decision modifying its internal regulations establishing the “Commission for the Evaluation of Diagnostic, Prognostic, and Predictive Technologies (CEDiag)”.

This Commission is responsible for preparing the opinions and decisions of the HAS and HAS commissions (Transparency Committee, the National Committee for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS), the Economic and Public Health Evaluation Commission (CEESP)) whether or not they meet as an inter-commission, relating to the evaluation of health technologies for diagnostic, prognostic or predictive purposes.

The details on the CEDiag organization and functioning are provided in the HAS document “Rules of Procedure of the CEDiag”, published in early April 2023.

See the details in French here (decision on CEDiag) and here (CEDiag rules of procedure)

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.